HER2 Expression Discordance between Ductal Carcinoma In situ and Invasive Breast Carcinoma. How to Analyze Oncotype DX
Keywords:HER2, DCIS, FISH, ODX.
Although histologically invasive breast carcinomas can be of no special subtype (ductal) or of special subtypes (as lobular carcinoma), based on their immunohistochemical and molecular features, they are subclassified in four different groups: luminal A, luminal B (with and without HER2 overexpression), HER2 subtype and triple negative. They vary in their gene expression signature, biological potential and clinical course. Luminal A subtype is considered to have a better prognosis and most are treated with hormone therapy alone after surgery because they express hormone receptors and show a low proliferation index. Oncotype DX (ODX) is a molecular score assay that estimates recurrence risk for early-stage hormone receptor-positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer. It can predict which tumours may benefit from adjuvant chemotherapy. It has been reported that occasionally a breast carcinoma can have immunohistochemical and molecular differences between the in situ and the invasive components. We report one case that may lead us to misinterpret ODX results, where the in situ ductal component amplified HER2 gene while invasive component did not. Therefore, carefulness must be taken when evaluating ODX results, and be sure that we are evaluating the invasive component.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917. https://doi.org/10.1002/ijc.25516 DOI: https://doi.org/10.1002/ijc.25516
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874. https://doi.org/10.1073/pnas.191367098 DOI: https://doi.org/10.1073/pnas.191367098
Goldrich A, Wood WC, Coates AS, Gelder RD, Thrulmann B, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011; 22(8): 1736-47. https://doi.org/10.1093/annonc/mdr304 DOI: https://doi.org/10.1093/annonc/mdr304
Park K, Han S, Kim HJ, Kim J, Shin E. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology 2006; 48(6): 702-7. https://doi.org/10.1111/j.1365-2559.2006.02403.x DOI: https://doi.org/10.1111/j.1365-2559.2006.02403.x
Aguiar FN, Mendes HN, Bacchi CE, Carvalho FM. Comparison of nuclear grade and immunohistochemical features in situ and invasive components of ductal carcinoma of breast. Rev Bras Ginecol Obstet 2013; 35(3): 97-102. https://doi.org/10.1590/S0100-72032013000300002 DOI: https://doi.org/10.1590/S0100-72032013000300002
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817e26. https://doi.org/10.1056/NEJMoa041588 DOI: https://doi.org/10.1056/NEJMoa041588
Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor positive breast cancer. J Clin Oncol 2006; 24: 3726e34. https://doi.org/10.1200/JCO.2005.04.7985 DOI: https://doi.org/10.1200/JCO.2005.04.7985
Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2016; 34: 1134e50. https://doi.org/10.1200/JCO.2015.65.2289 DOI: https://doi.org/10.1200/JCO.2015.65.2289
Henry NL, Somerfield MR, Abramson VG, Allison KH, Anders CK, Chingos DT, et al. Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer: American society of clinical oncology endorsement of cancer care Ontario guideline recommendations. J Clin Oncol 2016; 34: 2303e11. https://doi.org/10.1200/JCO.2015.65.8609 DOI: https://doi.org/10.1200/JCO.2015.65.8609
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010; 134(7): e48-72.
Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in breast cancer working group. J Natl Cancer Inst 2011; 103(22): 1656-64. https://doi.org/10.1093/jnci/djr393 DOI: https://doi.org/10.1093/jnci/djr393
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/ College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31(31): 3997-4013. https://doi.org/10.1200/JCO.2013.50.9984 DOI: https://doi.org/10.1200/JCO.2013.50.9984
Latta EK, Tjan S, Parkes RK, O'Malley FP. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol 2002; 15(12): 1318-25. https://doi.org/10.1097/01.MP.0000038462.62634.B1 DOI: https://doi.org/10.1097/01.MP.0000038462.62634.B1
Allred DC, Clark GM, Molina R, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992; 23: 974-979. https://doi.org/10.1016/0046-8177(92)90257-4 DOI: https://doi.org/10.1016/0046-8177(92)90257-4